Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lupin Boss On Getting Biosimilar Manufacturing Right, Albuterol Outlook

Executive Summary

Lupin managing director tells Scrip that manufacturing competence will be a “big advantage” in the biosimilars space, and also believes that the US albuterol market remains “very lucrative” despite the entry of authorized generics.

You may also be interested in...



Lupin’s ProAir Rival Has 'Moved Ahead' Despite CRL

Lupin is staring at stretched launch timelines in the US for its generic ProAir following a Complete Response Letter, but the company maintains that its application has progressed and the market opportunity for the product remains attractive.

US Setback For Lupin’s GxProAir But Application Has 'Moved Ahead'

Lupin is staring at stretched launch timelines in the US for its generic ProAir following a Complete Response Letter, but the company maintains that its application has progressed and the market opportunity for the product remains attractive.

Cipla Claims Pricing Advantage For Albuterol In US

Cipla, which expects to enter the US albuterol inhalation market later this year, believes that it has the cost competitiveness to price “significantly lower” than competition and take a “fair share” of a market that recently saw the arrival of authorized generics.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC125413

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel